- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Pulmonary arterial hypertension (PAH)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 602KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 112KB)
Macitentan with tadalafil – November 2024
Macitentan with Tadalafil; Tablet containing macitentan 10 mg with tadalafil 40 mg; Opsynvi®
Last updated
30 May 2025